Research on how cancer spreads through the body. Covers metastasis monitoring, bone metastasis, and nanoparticle treatments.
Researchers found that dual-positive cells, a type of circulating tumor cell, are associated with shorter survival times and increased risk of metastasis in patients with advanced breast cancer. The study highlights the potential importance of these under-studied cells in breast cancer progression.
Patients with type 2 diabetes and brain metastases who used GLP-1 receptor agonists showed a significant reduction in all-cause mortality. The use of these medications was associated with reduced neuroinflammation, preservation of the blood-brain barrier, and lowered oxidative stress and mitochondrial dysfunction.
Researchers at the University of Gothenburg have identified a protein, ATF4, linked to increased metastasis and recurrence in lung cancer. The study reveals that older individuals' tumors are smaller and grow more slowly, yet more likely to have spread when detected.
Ochsner MD Anderson Cancer Center will be the first in the southern US to offer biology-guided radiotherapy (BgRT), a breakthrough treatment that uses cancer biology to guide radiotherapy delivery. This new therapy aims to provide more focused and accurate treatment with fewer side effects for patients.
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
Researchers developed CAR macrophages that crossed the blood-brain barrier, recognizing and destroying cancer cells and releasing signals to harm nearby tumors. The treatment showed significant reductions in brain tumor progression and increased survival in preclinical models.
Researchers identify UBR5 as a critical tumor suppressor that modulates Snail's stability, facilitating metastasis. UBR5 maintains epithelial phenotype by targeting Snail for degradation, while its deficiency promotes Snail stabilization and metastatic cascade.
Researchers developed a molecular monitoring approach to identify patients with muscle-invasive bladder cancer who can safely preserve their bladder without compromising cancer outcomes. The study found that ultra-sensitive testing of tumor-derived DNA in blood and urine may help predict metastatic risk and identify patients with an ex...
Researchers are developing a new compound that can break down MDM2, a cancer-driving protein often found in triple-negative breast cancer, showing promise in shrinking tumors. The goal is to create an entirely new class of therapies for this aggressive and difficult-to-treat form of the disease.
A study reveals that senescence plays a paradoxical role in postpartum breast cancer, promoting tumor formation while also aiding tissue repair. Targeting senescent cells during mammary gland involution could potentially reduce the risk of this form of cancer.
A major study has shown that tumour stage at diagnosis is strongly linked to childhood cancer survival across six different cancers. Researchers analysed data from 9,883 children in 27 countries and found significant variation in three-year survival rates between regions, particularly in the UK and Ireland.
A research team at Tohoku University has made a groundbreaking discovery about the anatomy of lymph nodes, revealing new structures that challenge traditional ideas about immune system function. The findings have significant implications for understanding and treating conditions like lymphedema and cancer.
In a mouse study, researchers successfully used RNA micelles to shrink metastasized tumors in lungs by delivering chemotherapy drugs and an RNA molecule that blocks cancer survival. The treatment significantly reduced tumor growth and improved outcomes for mice with colorectal cancer lung metastasis.
The PATINA trial demonstrates a significant progression-free survival benefit with palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. The study showed a median progression-free survival of 44.3 months, compared to 29.1 months in the control arm.
Researchers identified a targetable driver of brain metastases in inflammatory breast cancer, promoting tumor invasion and triggering brain inflammation via the CXCR2 signaling pathway. Targeting sEcad or the CXCR2 pathway may treat or prevent brain metastasis.
A new AI-powered model predicts patient survival and risk stratification for spinal metastasis, allowing for more informed treatment decisions. The model achieved high predictive accuracy using large-scale clinical data from Japanese patients.
Research reveals that chemotherapy alters the gut microbiota, producing indole-3-propionic acid, which travels to the bone marrow and rewires immune cell production. This leads to a metastasis-refractory state in preclinical models and improved survival outcomes in patients with colorectal cancer.
Researchers discovered that cancer cells lower their surface tension to evade immune detection, making them harder to attack. By understanding this process, scientists hope to develop new treatments to prevent metastasis and eliminate dormant cancer cells.
A new nanodrug called Nano-273 could offer improved survival for patients with pancreatic and lung cancers by activating the immune system and blocking tumor growth. The drug, developed by University of Houston researcher Wei Gao, has shown promising results in early studies.
Researchers found that ovarian cancer transforms the omentum into an environment that favors tumor spread. The study analyzed tissue samples from 15 patients and created a cell atlas of the omentum in diseased and healthy states.
A new study from Texas A&M University reveals that circadian disruptions change the structure of mammary glands, weaken immune defenses, and fuel aggressive breast cancer. Disabling an immune checkpoint molecule called LILRB4 helps restore the immune system's ability to fight back.
A blood test may help doctors identify which patients with colon cancer can benefit from anti-inflammatory medication and chemotherapy after surgery. The test measures circulating tumor DNA levels, and high-risk patients who test positive see improved survival rates when taking celecoxib with chemotherapy.
A prospective multicenter trial validated an improved method for predicting treatment benefits in hormone receptor-positive metastatic breast cancer with bone metastases. Metabolic change assessed by FDG-PET/CT accurately predicted progression-free survival as early as 12 weeks after treatment initiation.
Researchers have developed an AI-driven method to uncover genetic interactions driving cancer progression. The approach highlights complex interplay between genes allowing malignant cells to gain momentum and reveals previously hidden cancer drivers.
A new AI-based method can differentiate between tumour progression and radiation necrosis with high accuracy, enabling more accurate identification and treatment of late-stage cancer patients. This discovery could lead to better treatments for brain metastasis patients treated with stereotactic radiosurgery.
Scientists at Penn Vet have identified two genes, Ctnna1 and Bcl2l13, that suppress metastasis in preclinical models of colorectal cancer. These findings could lead to better treatments and therapies for patients with metastatic disease.
Researchers discovered breast cancer modifies lymphatic vessels to facilitate its spread. A specific protein, Matrix Gla protein (MPG), enables cancer cells to bind to lymphatic vessels, supporting metastasis. Understanding this process could lead to targeted therapies and improved patient outcomes.
Researchers discovered that synthetic stress hormone dexamethasone can combat therapy-resistant breast cancer metastases in mice trials. The drug activates the glucocorticoid receptor, suppressing estrogen receptor production and slowing tumor growth. Further studies are needed to confirm these findings in patients with breast cancer.
Researchers at UC Riverside and City of Hope have developed a novel Pin1 degrading compound that suppresses pancreatic cancer peritoneal metastases. The treatment targets not only cancer cells but also tumor-supporting cells, potentially overcoming treatment resistance.
Researchers identified a cholesterol metabolite called hydroxycholesterol that suppresses the immune system's ability to attack cancer, leading to increased metastasis. The team discovered a line of communication used by immune cells and cancer cells that stimulates breast cancer progression.
Researchers studied MALAT1 levels in a woman with triple-negative breast cancer, finding high levels at diagnosis and decreased while receiving treatment. Notably, levels increased at a distant metastatic site, suggesting MALAT1's role in TNBC's spread. The study informs future treatments and potential clinical trials.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found that aging accelerates pancreatic cancer progression, leading to faster tumor growth and metastasis. By understanding the impact of age on the tumor microenvironment, they developed a new approach to treating this disease in frail patients.
Biomechanical forces play a crucial role in regulating cancer invasion and metastasis by modulating cell membrane topology, actin cytoskeletal remodeling, and mechanical stress adaptation. The review highlights the importance of three-dimensional tumor models and novel therapies targeting mechanical signaling pathways to inhibit invasion.
Researchers at Arizona State University discovered that SerpinB3 plays a natural role in the body's wound-healing process, helping skin recover after damage. The protein helps activate keratinocytes to rebuild tissue and improve skin strength.
Researchers at OHSU develop a promising drug SU212 to treat intractable cases of triple-negative breast cancer. The molecule binds to and degrades the enzyme enolase 1, suppressing tumor growth and metastasis in humanized mouse models.
A study reveals how colorectal tumors use TGF-β to prevent immune cells from reaching and attacking the tumor. The researchers suggest strategies to improve immunotherapy efficacy by blocking this dual barrier and identifying new therapeutic targets.
Stuart S. Martin, PhD, has been appointed Chair of the Department of Pharmacology & Physiology at UMSOM, bringing over 20 years of success in advancing basic science research efforts and developing new drug therapies. His groundbreaking discovery of microtentacles on cancer cells promises to lead to new life-extending therapies.
A new USC study identified five genes linked to aggressive prostate cancer in people of African descent, including ATM, BRCA2, CHEK2, HOXB13 and PALB2. The researchers developed a method combining genetic risk scores with family history and specific variant presence for personalized monitoring and treatment strategies.
A new case report describes the successful treatment of a 37-year-old woman with HER2-positive breast cancer that had spread to the membranes surrounding the brain and spinal cord. Trastuzumab deruxtecan, an antibody-drug conjugate, improved the patient's neurological symptoms and reduced cancer growth.
Researchers have discovered a new way to understand cancer and its vulnerabilities by targeting FSP1, a protein that helps cancer cells survive. The study found that FSP1 inhibitors can effectively reduce the growth of metastatic melanoma cells in lymph nodes.
Researchers developed nanomachines that can function stably within living organisms, enabling starvation therapy to treat refractory pancreatic cancer. This approach improved treatment outcomes by depleting essential nutrients for cancer cell growth.
Researchers outline biological mechanisms of breast cancer brain metastasis, highlighting key molecular pathways and the role of the brain microenvironment. The review also discusses emerging therapeutic approaches and calls for cross-disciplinary collaboration to improve outcomes.
Researchers found that tumor-associated macrophages produce acetate through a metabolic interaction involving lactate and the lipid peroxidation–ALDH2 pathway. This acetate promotes histone H3 acetylation and epithelial-mesenchymal transition in hepatocellular carcinoma cells, enhancing metastasis.
Biologists at Cold Spring Harbor Laboratory have made a significant discovery that could lead to better patient outcomes for ER+ breast cancer patients. Inhibiting the BPTF protein in mice can slow cancer metastasis and restore tumors' susceptibility to hormone therapy, offering new hope for treating resistant forms of the disease.
Researchers at MD Anderson have discovered a previously unknown mechanism that explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer. The study also identifies a new biomarker for improved immunotherapy responses in solid tumors.
Han Xiao, a pioneer in medicinal chemistry, has been awarded the David W. Robertson Award for his contributions to therapeutic discovery. His research focuses on developing chemical tools to probe and manipulate biological systems, with a focus on cancer therapy.
Researchers suggest chemotherapy drugs may be responsible for 'chemo brain' symptoms, citing reduced lymphatic vessel growth and impaired cognitive function. The study highlights the need to consider long-term neurological side effects of cancer treatment on quality of life.
Researchers at UMass Amherst have developed a nanoparticle-based vaccine that prevents melanoma, pancreatic and triple-negative breast cancer in mice. The vaccine achieved remarkable survival rates, with up to 88% of vaccinated mice remaining tumor-free.
Researchers at UCSF have discovered a novel combination of immunotherapies that can reprogram the immune environment of colon cancer tumors in the liver. This therapy often eliminated tumors entirely in preclinical models, showing promise for treating patients with advanced colorectal cancer.
The ASPIRE trial is a Phase III clinical study investigating whether adding chemotherapy to standard treatments can extend survival in men with advanced prostate cancer. The trial aims to determine the effectiveness of combining docetaxel with hormone therapy and apalutamide.
Research presents evidence suggesting that metabolically active visceral fat is associated with more advanced stages of endometrial cancer and lymph node metastases. The study found no strong correlation between visceral fat volume and its metabolic activity.
Researchers discovered that an enzyme called EZH2 drives triple negative breast cancer cells to divide abnormally, enabling them to spread. Inhibiting EZH2 with drugs like tazemetostat restored order to dividing cells and thwarted the spread of TNBC cells.
A Virginia Tech oncologist is championing a precise approach to treating acute myeloid leukemia by tracking subtle molecular changes in patients. His work aims to identify signs of potential relapse and tailor treatment for each individual with this rare blood cancer.
New MSK research explores the importance of tumor location in metastasis, regulatory T cells' role in pain management, and the effectiveness of proton therapy for leptomeningeal metastasis. The study found that different organ sites select for different cell types present in primary tumors, affecting their viability.
Researchers identify three primary UPR pathways and their downstream cascades, which play a crucial role in the differentiation of osteoblasts and osteoclasts. Targeting these pathways with emerging drugs may alleviate bone-related events and kill tumors localized in bones.
Researchers identified NBL1 as a key driver of ovarian cancer metastasis through its activation of the Jak/Stat3 pathway. NBL1 expression levels strongly correlated with advanced clinical stage and poor survival outcomes.
DDX17 promotes HCC metastasis via the β-catenin/TCF4 pathway, inducing EMT and enhancing migration/invasion. The β-catenin/TCF4/DDX17 feedback loop is essential for HCC dissemination.
A new algorithm developed by Núria Malats and her team can accurately predict the presence of metastasis in pancreatic cancer using medical images. The PMPD algorithm has shown promising results, classifying 56% of metastases with high accuracy and potentially avoiding unnecessary surgeries.
Research by Angela Riedel and team identified fibroblastic reticulum cells as main players in reprogramming lymph nodes, corrupting monocytes and blocking T cell activity. Targeted TLR4 blockade combined with PD1 immunotherapy can restore T-cell activity and reduce distant metastasis.
A new study from Mizzou's College of Veterinary Medicine analyzed the effects of radioactive iodine therapy on thyroid cancer in dogs. The research found that tailoring the dose of radiation more precisely for each dog could improve outcomes and potentially lead to more targeted care.